Efavirenz

Efavirenz

Form: Tablet & Capsule

Strength: Tab: 200 mg, 600 mg; Cap: 50 mg, 100 mg, 200 mg

Reference Brands: Sustiva®(US); Stocrin®(EU)

Category: Anti Viral

Efavirenz Tablets are widely used as part of combination therapy for HIV-1 treatment, classified under NNRTIs. Commonly available in 600 mg and pediatric strengths, Efavirenz is also found in fixed-dose combinations like Atripla®. On PharmaB2B platforms, bulk buyers and distributors can connect with GMP-certified manufacturers for high-quality Efavirenz products. Ideal for hospitals, HIV programs, NGOs, and government tenders, PharmaB2B supports cost-effective and compliant procurement across global markets. Whether sourcing single or combo formulations, buyers benefit from reliable supply chains and competitive pricing. Choose PharmaB2B for trusted suppliers of Efavirenz and other essential antiretrovirals.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.